Publications by authors named "M F PROTIC"
Background: Mirikizumab, a humanised monoclonal antibody that inhibits IL-23p19, is effective in moderate-to-severe ulcerative colitis. We aimed to evaluate the efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease.
Methods: VIVID-1 was a global phase 3, randomised, double-blind, double-dummy, placebo-controlled and active-controlled, treat-through study.
Background: Bowel urgency is a highly disruptive and bothersome symptom experienced by patients with inflammatory bowel diseases (IBD), (ulcerative colitis [UC], and Crohn's disease [CD]). However, the burden of bowel urgency among patients with varying experiences in targeted treatment has not been consistently assessed. This real-world study explored the clinical and health-related quality of life burden of bowel urgency among patients with IBD with differing treatment experiences.
View Article and Find Full Text PDFArticle Synopsis
- Fatigue is a significant and often overlooked symptom in Crohn's disease, and the study evaluated how the medication mirikizumab affects this symptom over a 104-week period.
- A total of 191 patients were included, with different dosages of mirikizumab administered, and fatigue levels were measured using the FACIT-F questionnaire.
- Results showed that patients receiving mirikizumab reported significant and sustained improvements in fatigue and quality of life, with better fatigue scores correlating well with improvements in clinical measures, but not with inflammation markers.
Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial.
Clin Gastroenterol Hepatol
September 2024
Article Synopsis
- The study evaluated the effectiveness of mirikizumab in achieving histologic and endoscopic healing in Crohn's disease over 52 weeks, with a focus on biopsy samples taken at various intervals.
- Results showed that participants receiving 1000 mg of mirikizumab had significantly higher rates of histologic response (66%) and remission (26%) at week 12 compared to those receiving a placebo.
- A strong correlation was noted between early combined histologic and endoscopic responses and subsequent endoscopic remission at the one-year mark, demonstrating the therapy's potential long-term benefits.
Aim: Multidisciplinary management of metastatic colorectal liver metastases (CRLM) is still challenging. To assess postoperative complications in initially unresectable or borderline resectable CRLM, the prospective EORTC-1409 ESSO 01-CLIMB trial capturing 'real-life data' of European centres specialized in liver surgery was initiated.
Material And Methods: A total of 219 patients were registered between May 2015 and January 2019 from 15 centres in nine countries.